Hermetica Superfood Encyclopedia
The Short Answer
Rauvolfia vomitoria contains indole alkaloids—principally reserpine, ajmaline, yohimbine, and ajmalicine—that deplete catecholamine stores at adrenergic nerve terminals and modulate adrenoreceptor signaling, producing antihypertensive and antipsychotic effects. In vitro studies demonstrate that its β-carboline-enriched extract induces apoptosis via caspase-8/caspase-3/PARP cleavage in ovarian cancer cell lines (IC₅₀ ≈ 300 µg/mL) and achieves a 1.7- to 7-fold dose reduction index when combined with cisplatin, though no large human clinical trials have confirmed these effects.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordRauvolfia vomitoria benefits
Rauvolfia vomitoria — botanical close-up
Health Benefits
**Antihypertensive Activity**
Reserpine and related heteroyohimbine alkaloids (reserpiline, isoreserpiline) deplete peripheral norepinephrine from sympathetic nerve endings, reducing vascular tone and blood pressure; this mechanism underpins the plant's central role in Yoruba ethnomedicine for hypertension management.
**Antipsychotic and Sedative Effects**
Reserpine's depletion of central monoamine stores produces tranquilizing effects historically exploited in traditional African psychiatry; the compound served as one of the first pharmacological leads for modern antipsychotic drug development.
**Anticancer Potential**
β-carboline and indole alkaloid-enriched fractions of leaf and root extracts reduced viability of SHIN-3, OVCAR-5, and OVCAR-8 ovarian cancer cell lines by 60–80% at 400 µg/mL with minimal toxicity to noncancerous MRC-5 cells (28% reduction), and completely inhibited colony formation in soft agar assays.
**Antimicrobial Activity**
Aqueous and ethanolic extracts demonstrated broad-spectrum inhibitory activity with inhibition zones of 24 mm against Aspergillus niger, 22 mm against Klebsiella pneumoniae, and 18 mm against Pseudomonas aeruginosa in disk diffusion assays, attributable in part to saponins, alkaloids, and phenolic compounds.
**Antioxidant and Hepatoprotective Properties**
Phytol, vitamin E, lupeol, squalene, and sitosterol present in leaf extracts contribute to free radical scavenging capacity (total phenolic content 17.04 ± 0.20 mg gallic acid equivalents per gram); hepatoprotective effects have been suggested in animal models, though paradoxically chronic high-dose administration causes liver damage.
**Antidepressant-Like Activity**
Preclinical rodent models indicate that leaf and root extracts modulate monoaminergic neurotransmission in ways consistent with antidepressant behavior, likely via ajmalicine's interaction with serotonin and adrenergic receptors.
**Hypocholesterolemic Effects**
Phytosterols (campestrol, sitosterol) and vaccenic acid identified in root extracts (cis-vaccenic acid at 32.13% of root GC-MS profile) may compete with intestinal cholesterol absorption and modulate lipid metabolism, contributing to cardiovascular risk reduction reported in traditional use contexts.
Origin & History
Natural habitat
Rauvolfia vomitoria is a tropical shrub native to sub-Saharan Africa, growing widely across West and Central Africa including Nigeria, Togo, Benin, Ghana, and the Democratic Republic of Congo. It thrives in humid forest margins, riverbanks, and secondary vegetation at low to mid elevations, preferring well-drained, fertile soils in warm, equatorial climates. The plant is both wild-harvested and cultivated near traditional communities, with roots, bark, and leaves all utilized depending on regional ethnobotanical practice.
“Rauvolfia vomitoria has been integral to West and Central African ethnomedicine for centuries, serving as a primary treatment for hypertension, febrile illnesses, psychosis, and snake envenomation across Yoruba (Nigeria), Ewe (Togo/Benin), and Bantu-speaking communities. In Yoruba medicine, the root bark is among the most recognized antihypertensive botanicals, often prescribed by herbalists as a decoction alongside dietary modifications, reflecting a sophisticated empirical recognition of its vasodepressant properties that predates the isolation of reserpine. Colonial-era botanical surveys in West Africa in the late 19th and early 20th centuries documented its psychiatric uses as a 'madness cure,' contributing to subsequent pharmaceutical interest that paralleled investigations of the closely related Rauvolfia serpentina in South Asia—culminating in reserpine's commercial introduction as one of the first antihypertensive drugs in the 1950s. The species name 'vomitoria' alludes to its emetic properties at higher doses, historically exploited in purification rituals and as an antidote for poisoning in certain Central African traditions.”Traditional Medicine
Scientific Research
The current evidence base for Rauvolfia vomitoria consists predominantly of in vitro cell culture studies and rodent toxicological models, with no published large-scale, randomized controlled human clinical trials identified in the peer-reviewed literature. In vitro anticancer work using ovarian cancer cell lines (SHIN-3, OVCAR-5, OVCAR-8) demonstrated dose-dependent cytotoxicity with quantified IC₅₀ values (~300 µg/mL) and synergistic dose reduction indices (1.7–7-fold) with cisplatin, representing a promising but early-stage preclinical signal. Chronic oral toxicity studies in Wistar rats at doses of 75, 150, and 300 mg/kg produced dose-dependent hepatotoxicity with elevated liver weights and histologically confirmed lesions, establishing a meaningful safety concern that must be weighed against therapeutic potential. Ethnopharmacological surveys from Togo and Benin document consistent traditional use for asthma, hypertension, and psychiatric conditions, providing external validity for biological plausibility but not substituting for controlled human trials; the overall evidence strength remains at the preclinical stage.
Preparation & Dosage
Traditional preparation
**Traditional Decoction (Root Bark)**
Roots or root bark are boiled in water for 20–40 minutes; administered orally as a tea in West African traditional medicine for hypertension and psychosis at volumes and concentrations that are not formally standardized.
**Aqueous Leaf Extract**
04 mg GAE/g has been documented in standardized research preparations
Leaves are macerated or boiled to produce aqueous extracts used topically and orally in Togo and Benin for asthma and inflammatory conditions; total phenolic content of 17..
**Ethanolic Extract (Research Grade)**
Laboratory studies have used ethanol-extracted preparations at concentrations of 100–400 µg/mL in cell culture models; no equivalent human supplemental dose has been established or validated.
**No Commercially Standardized Supplement Form Established**
Unlike Rauvolfia serpentina (Indian snakeroot), no globally marketed standardized Rauvolfia vomitoria supplement with defined reserpine content or alkaloid standardization is widely available; formulations referencing 'African Rauvolfia' should be evaluated critically.
**Effective Human Dose Range**
300 mg/kg (chronic) and the pharmacological potency of reserpine, any human use outside formal clinical investigation is not supported by current evidence
Not established. Given rodent hepatotoxicity at .
**Timing Notes**
Traditional preparations are typically administered in divided doses morning and evening; no pharmacokinetic data on peak concentration or optimal dosing intervals for human use are available.
Nutritional Profile
Rauvolfia vomitoria is not consumed as a food and therefore lacks a conventional macronutrient profile; its relevance lies in its phytochemical composition. Leaf GC-MS analysis identifies squalene (18.69%), phytol (16.47%), n-hexadecanoic acid/palmitic acid (15.68%), 7-tetradecenal (12.90%), and 9,12,15-octadecatrienoic acid ethyl ester (9.56%) as dominant volatile and semi-volatile constituents across 22 identified phytochemicals. Root GC-MS profiling reveals cis-vaccenic acid (32.13%), n-hexadecanoic acid (15.41%), (E)-9-octadecenoic acid ethyl ester/oleic acid ethyl ester (9.83%), cyclohexanecarbonitrile (9.45%), and 8H-azecino[5,4-b]indol-8-one (7.66%) among 16 identified compounds. Alkaloid content includes quantified ajmaline, yohimbine, reserpine, and ajmalicine; total alkaloid content is approximately 1.92% by mass in crude extracts, with flavonoids at 1.15% and saponins at 1.12%; total phenolic content in aqueous leaf extract measures 17.04 ± 0.20 mg gallic acid equivalents per gram. Phytosterols including campestrol and sitosterol are present, contributing to potential hypocholesterolemic bioavailability via intestinal absorption competition with dietary cholesterol.
How It Works
Mechanism of Action
The primary antihypertensive mechanism centers on reserpine, which irreversibly inhibits vesicular monoamine transporter 2 (VMAT2), preventing repackaging of norepinephrine, dopamine, and serotonin into synaptic vesicles and causing their cytoplasmic degradation by monoamine oxidase, thereby depleting peripheral and central catecholamine stores and reducing sympathetic vascular tone. Ajmaline acts as a sodium channel blocker (class IA antiarrhythmic mechanism), slowing cardiac conduction velocity, which explains both antiarrhythmic properties and cardiac toxicity risk. Ajmalicine (δ-yohimbine) functions as an α₁-adrenoceptor antagonist causing vasodilation, while yohimbine acts primarily as a selective α₂-adrenoceptor antagonist with effects on both peripheral vasomotor tone and central noradrenergic signaling. In oncological models, the β-carboline alkaloid fraction activates the extrinsic apoptotic cascade through caspase-8 cleavage, downstream activation of caspase-3, and PARP proteolysis in a time- and dose-dependent manner, while squalene and phytol contribute antioxidant and membrane-stabilizing activity through quenching of reactive oxygen species and modulation of lipid peroxidation pathways.
Clinical Evidence
No phase II or phase III human clinical trials specifically investigating standardized Rauvolfia vomitoria extracts for hypertension, cancer, or any primary indication have been identified in publicly available literature. The most quantitatively detailed clinical-proxy data derive from in vitro ovarian cancer studies showing 60–80% cell viability reduction at 400 µg/mL and complete soft-agar colony inhibition, outcomes that cannot be directly translated to human therapeutic doses. Rodent acute toxicity studies established an oral LD₅₀ exceeding 5000 mg/kg body weight, while chronic 90-day rat studies at 300 mg/kg demonstrated significant hepatotoxicity, providing the most rigorously quantified safety benchmarks currently available. Confidence in therapeutic efficacy for any indication in humans remains low due to absence of controlled clinical data, and the plant's alkaloid complexity—particularly reserpine and ajmaline—introduces cardiovascular and hepatic risks that demand clinical investigation before supplemental use can be responsibly recommended.
Safety & Interactions
Chronic oral administration of Rauvolfia vomitoria extract at 300 mg/kg in Wistar rats causes confirmed hepatotoxicity with elevated relative liver weight and histologically verified liver lesions; while the acute oral LD₅₀ exceeds 5000 mg/kg in rats, sub-lethal chronic exposures present a clinically meaningful hepatic safety concern that precludes casual supplemental use. Reserpine—the principal antihypertensive alkaloid—is contraindicated in patients with a history of depression, peptic ulcer disease, ulcerative colitis, or Parkinson's disease, and causes adverse effects including nasal congestion, bradycardia, sedation, and paradoxical depression at antihypertensive doses; it exhibits significant pharmacodynamic interactions with antihypertensive agents (additive hypotension), MAO inhibitors (hypertensive crisis risk), tricyclic antidepressants (antagonism of reserpine's effects), and levodopa (reduced efficacy). Ajmaline carries documented risks of QT prolongation, Brugada syndrome unmasking, and hepatotoxicity and should not be combined with other sodium channel blockers, antiarrhythmics, or QT-prolonging agents including certain antibiotics and antifungals. Rauvolfia vomitoria is contraindicated in pregnancy (reserpine crosses the placenta and can cause neonatal respiratory depression, cyanosis, and feeding difficulties), during lactation (alkaloid excretion in breast milk), and in individuals with pre-existing hepatic disease; due to the presence of potent cardiovascular alkaloids, self-administration without medical supervision is strongly discouraged.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Laro (Yoruba)Rauvolfia vomitoria Afzel.Akanta (Yoruba)Rauvolfia vomitoria (African Serpentwood)Wuf-wuf (Hausa)African snakerootSwizzle stick plantPoison devil's pepper
Frequently Asked Questions
What is Rauvolfia vomitoria used for in traditional medicine?
In Yoruba and broader West African ethnomedicine, Rauvolfia vomitoria root bark decoctions are used primarily to treat hypertension, psychosis, febrile illnesses, and as an antidote for snake envenomation. Communities in Togo and Benin also use it in primary asthma care, and its emetic properties have been exploited in ritual purification contexts. These uses reflect the pharmacological activity of its indole alkaloids, particularly reserpine's monoamine-depleting antihypertensive and tranquilizing effects.
Is Rauvolfia vomitoria safe to take as a supplement?
Rauvolfia vomitoria is not considered safe for unmonitored supplemental use given its documented hepatotoxicity at chronic doses of 300 mg/kg in animal models and the inherent dangers of its alkaloid profile—reserpine can cause severe depression, bradycardia, and neonatal harm, while ajmaline can unmask Brugada syndrome and prolong QT interval. No standardized human supplement dose has been established, and the absence of human clinical safety trials means risk cannot be adequately quantified. Medical supervision is essential if this plant is being considered therapeutically.
Does Rauvolfia vomitoria have anticancer properties?
Preclinical in vitro studies have shown that Rauvolfia vomitoria extracts reduce the viability of three ovarian cancer cell lines (SHIN-3, OVCAR-5, OVCAR-8) by 60–80% at 400 µg/mL and synergize with cisplatin with dose reduction indices of 1.7- to 7-fold, likely via caspase-8/caspase-3/PARP-mediated apoptosis activated by β-carboline alkaloids. However, these are laboratory (cell culture) findings only—no human clinical trials have tested its anticancer efficacy or safety in cancer patients, and the concentrations used in vitro cannot be directly translated to human doses.
How does reserpine in Rauvolfia vomitoria lower blood pressure?
Reserpine irreversibly inhibits vesicular monoamine transporter 2 (VMAT2), the protein responsible for packaging norepinephrine and other catecholamines into synaptic vesicles in sympathetic nerve terminals. Without vesicular storage, these neurotransmitters are degraded by intracellular monoamine oxidase, depleting peripheral sympathetic tone and reducing both heart rate and vascular resistance, thereby lowering blood pressure. Ajmalicine in the same plant adds complementary vasodilation through α₁-adrenoceptor antagonism.
What are the drug interactions of Rauvolfia vomitoria?
The reserpine content of Rauvolfia vomitoria creates significant interactions with antihypertensive drugs (additive hypotension risk), MAO inhibitors (risk of hypertensive crisis due to monoamine accumulation), tricyclic antidepressants (pharmacological antagonism), and levodopa (reduced dopaminergic efficacy relevant to Parkinson's patients). The ajmaline alkaloid can interact dangerously with other sodium channel blockers, class I antiarrhythmics, and QT-prolonging agents including certain fluoroquinolone antibiotics and azole antifungals. Patients on any cardiovascular or psychiatric medications should not use this plant without specialist medical oversight.
What is the difference between Rauvolfia vomitoria and Rauvolfia serpentina?
Both plants contain reserpine and related alkaloids, but Rauvolfia vomitoria is native to West Africa (particularly Nigeria) and has been the primary source in traditional Yoruba medicine, while Rauvolfia serpentina originates from India and Southeast Asia. Rauvolfia vomitoria generally contains higher concentrations of heteroyohimbine alkaloids like reserpiline and isoreserpiline compared to its Asian counterpart. The two species have comparable antihypertensive potency, though historical use and alkaloid profiles differ slightly between them.
What forms of Rauvolfia vomitoria are available as supplements, and which is most effective?
Rauvolfia vomitoria is available as whole root powder, standardized extracts (typically standardized to reserpine content), and dried root material in capsules or tinctures. Standardized extracts provide more consistent alkaloid levels and are generally preferred for reliable dosing, whereas whole root preparations vary in potency depending on growing conditions and harvest timing. Clinical efficacy is best documented with standardized extract forms that guarantee reserpine concentration.
Who should avoid taking Rauvolfia vomitoria supplements?
Rauvolfia vomitoria should be avoided by individuals with depression, a personal or family history of suicidal ideation, severe renal impairment, or pheochromocytoma, as reserpine can worsen depression and poses serious risks in these populations. Pregnant and nursing women should not use this herb due to potential teratogenic effects and alkaloid transfer through breast milk. Those with active peptic ulcer disease or on sympathomimetic medications should consult a healthcare provider before use, as the herb may increase gastrointestinal complications or create adverse interactions.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w rauvolfia-vomitoria-rauvolfia-vomitoria-afzel curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
